Alagebrium Chloride, a Novel Advanced Glycation End-Product Cross Linkage Breaker, Inhibits Neointimal Proliferation in a Diabetic Rat Carotid Balloon Injury Model |
Kim, Jin-Bae
(Cardiology Division, Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine)
Song, Byeong-Wook (Yonsei Cardiovascular Center and Cardiovascular Research Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine) Park, Sung-Ha (Cardiology Division, Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine) Hwang, Ki-Chul (Cardiology Division, Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine) Cha, Bong-Soo (Division of Endocrinology, Yonsei University College of Medicine) Jang, Yang-Soo (Cardiology Division, Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine) Lee, Hyun-Chul (Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine) Lee, Moon-Hyoung (Cardiology Division, Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine) |
1 | Vaitkevicius PV, Lane M, Spurgeon H, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A 2001;98:1171-5. DOI ScienceOn |
2 | Naka Y, Bucciarelli LG, Wendt T, et al. RAGE axis: animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 2004;24:1342-9. DOI ScienceOn |
3 | Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury: I. smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-33. |
4 | Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride(ALT-711), a novel glucose cross link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005;11:191-5. DOI ScienceOn |
5 | Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003;111:959-72. DOI ScienceOn |
6 | Wolffenbulttel BH, Boulanger CM, Crijns FR, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998;95:4630-4. DOI ScienceOn |
7 | Ettenson DS, Gotlieb AI. Centrosomes, microtubules, and microfilaments in the reendothelialization and remodeling of double-sided in vitro wound. Lab Invest 1992;66:722-33. |
8 | Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest 1994;93:1243-9. DOI ScienceOn |
9 | Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003;93:1159-69. DOI ScienceOn |
10 | Kass DA, Shapiro EP, Kaawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end product crosslink breakers. Circulation 2001;104:1464-70. DOI ScienceOn |
11 | Yue TL, Bao W, Gu JL, et al. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005;54:554-62. DOI |
12 | Cooper ME. Impotance of advanced glycation end products in diabetes associated cardiovascular and renal disease. Am J Hypertens 2004;17:31S-8S. DOI ScienceOn |
13 | Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95. DOI ScienceOn |
14 | Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes induced myocardial structural changes. Circ Res 2003;92:785-92. DOI ScienceOn |
15 | Park JS, Seok JH, Hong GR, Shin DG, Kim YJ, Shim BS. Types of in-stent restenosis and predictive factors for diffuse type in-stent restenosis. Korean Circ J 2001;31:1135-41. DOI |
16 | Nielsen TT, Botker HE. Percutaneous coronary intervention in diabetic patients: a problem? Horm Metab Res 2005;37(Suppl 1):83-9. DOI |
17 | Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. Circulation 1979;59:8-13. DOI ScienceOn |
18 | Ha JK, Han DC, Hwang KW, et al. Metabolic syndrome and risk of in-stent restenosis: clinical outcomes in patients undergoing percutaneous coronary intervention. Korean Circ J 2007;37:567-73. DOI |
19 | Park S, Lim S, Chang W, et al. The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway. Yonsei Med J 2008;49:592-600. DOI ScienceOn |
20 | Zhuo Z, Wang K, Penn MS, et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003;107:2238-43. DOI ScienceOn |
21 | Forbes JM, Yee LT, Thallas V, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004;53:1813-23. DOI ScienceOn |
22 | Shim CY, Park S, Yoon SJ, et al. Association of RAGE gene polymorphisms with in-stent restenosis in non-diabetic Korean population. Cardiology 2007;107:261-8. DOI ScienceOn |
23 | Susic D, Varagic J, Ahn J, Frohlich ED. Crosslink breakers: a new approach to cardiovascular therapy. Curr Opin Cardiol 2004;19:336-40. DOI ScienceOn |